Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by California State Teachers Retirement System

Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by California State Teachers Retirement System


California State Teachers Retirement System reduced its holdings in Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 5.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 493,898 shares of the company’s stock after selling 27,133 shares during the quarter. California State Teachers Retirement System owned approximately 0.10% of Elanco Animal Health worth $8,041,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the business. Hunter Associates Investment Management LLC increased its stake in Elanco Animal Health by 5.1% in the first quarter. Hunter Associates Investment Management LLC now owns 16,600 shares of the company’s stock valued at $269,000 after purchasing an additional 800 shares during the last quarter. Bfsg LLC grew its position in Elanco Animal Health by 8.2% during the first quarter. Bfsg LLC now owns 14,885 shares of the company’s stock valued at $242,000 after acquiring an additional 1,125 shares during the period. Allspring Global Investments Holdings LLC grew its position in Elanco Animal Health by 10.2% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 12,123 shares of the company’s stock valued at $181,000 after acquiring an additional 1,127 shares during the period. Commerce Bank grew its position in Elanco Animal Health by 3.8% during the fourth quarter. Commerce Bank now owns 33,665 shares of the company’s stock valued at $502,000 after acquiring an additional 1,223 shares during the period. Finally, Jones Financial Companies Lllp purchased a new stake in Elanco Animal Health during the fourth quarter valued at about $37,000. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Stock Performance

NYSE:ELAN opened at $12.34 on Friday. The company has a current ratio of 3.29, a quick ratio of 1.96 and a debt-to-equity ratio of 0.95. Elanco Animal Health Incorporated has a one year low of $8.52 and a one year high of $18.80. The business’s 50-day simple moving average is $15.49 and its 200 day simple moving average is $15.45.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last announced its quarterly earnings data on Wednesday, May 8th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.08. Elanco Animal Health had a positive return on equity of 5.98% and a negative net margin of 29.83%. The firm had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter in the prior year, the firm posted $0.45 earnings per share. Elanco Animal Health’s revenue for the quarter was down 4.1% compared to the same quarter last year. Research analysts forecast that Elanco Animal Health Incorporated will post 0.93 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Piper Sandler lowered their price target on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a research report on Monday, July 1st. Barclays decreased their target price on Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating for the company in a research report on Friday, June 28th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and an average target price of $17.57.

Get Our Latest Stock Report on ELAN

Insider Buying and Selling at Elanco Animal Health

In other news, Director William F. Doyle acquired 15,000 shares of the business’s stock in a transaction on Tuesday, May 21st. The shares were purchased at an average price of $16.98 per share, for a total transaction of $254,700.00. Following the completion of the purchase, the director now directly owns 76,330 shares of the company’s stock, valued at approximately $1,296,083.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.57% of the stock is currently owned by insiders.

Elanco Animal Health Profile

(Free Report)

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Further Reading

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)



Receive News & Ratings for Elanco Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Elanco Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.

link